6-Substituted Estradiol Derivatives for Selective Estrogen Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for estrogen-dependent and estrogen-independent tumors, face challenges such as systemic toxicity, side effects, and the conversion of estrogen-dependent cancers to estrogen-independent types, necessitating the development of new chemotherapeutic agents with improved tolerability and efficacy.
Innovation Solution
The development of 6-substituted estradiol compounds and their pharmaceutically acceptable salts or prodrugs, which can be administered in various forms, including nanoparticles or liposomes, to target and inhibit cancer cell growth by modulating estrogen receptors and triggering cellular stress mechanisms, thereby reducing side effects and enhancing treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (surgical procedures, radiation therapy, drug chemotherapies) are used, then cancer cell growth can be inhibited, but systemic toxicity and side effects increase
Solution Approach 1:
The patent applies local quality by modifying the estradiol molecule at specific positions (6-substitution) to create compounds that selectively target estrogen receptors in cancer cells while minimizing systemic effects. The specific chemical modifications at the 6-position of the estradiol core structure enable differential binding affinity and selective estrogen receptor modulation, achieving localized therapeutic effect with reduced global toxicity.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the estradiol derivative (different substituents at the 6-position, molecular weight, lipophilicity) to optimize the balance between efficacy and toxicity. By adjusting these chemical parameters, the compounds achieve enhanced selective binding to estrogen receptors while reducing non-specific interactions that cause systemic toxicity.
2Reliability
If Tamoxifen is used as an anti-estrogen agent, then estrogen binding to receptor sites is blocked, but structural deformation of receptors causes profound side effects
Solution Approach 1:
The patent modifies the molecular parameters of anti-estrogen compounds by introducing specific substituents at the 6-position of estradiol derivatives. These parameter changes alter the spatial and electronic properties of the compound, enabling it to bind to estrogen receptors without causing the severe structural deformation associated with Tamoxifen, thereby reducing side effects while maintaining receptor blocking activity.
Solution Approach 2:
The patent develops new chemotherapeutic agents that can be administered as short-acting prodrugs or compounds with controlled metabolic pathways. These compounds are designed to be metabolized rapidly into active forms at the target site, minimizing prolonged exposure and accumulation that could lead to severe side effects, while maintaining effective receptor modulation during the active phase.
3Reliability
If Tamoxifen is used for breast cancer treatment, then estrogen-dependent tumor growth is inhibited, but conversion to estrogen-independent tumor types occurs
Solution Approach 1:
The patent develops estradiol derivatives with multi-functional activity that can inhibit both estrogen-dependent and estrogen-independent tumor growth pathways. The compounds at the 6-position substitution enable dual mechanism of action: blocking estrogen receptor signaling in estrogen-dependent tumors while simultaneously inducing cellular stress responses and apoptosis in estrogen-independent tumor types, providing universal anti-cancer activity.
Solution Approach 2:
The patent converts the harmful effect of estrogen receptor signaling (which can drive tumor progression) into a beneficial therapeutic mechanism by using estradiol derivatives that trigger cellular stress responses and apoptosis through receptor activation followed by downstream cytotoxic effects. This approach turns the receptor signaling pathway, which could promote tumor growth, into a mechanism for tumor cell death.
4Object-affected harmful factors
If new chemotherapeutic agents are developed to improve tolerability, then side effects are reduced, but treatment efficacy may be compromised
Solution Approach 1:
The patent optimizes chemical parameters of the estradiol derivatives (substituent types at the 6-position, molecular weight, lipophilicity, hydrogen bonding capacity) to achieve the optimal balance between efficacy and tolerability. By carefully adjusting these parameters, the compounds maintain strong binding to estrogen receptors and effective tumor inhibition while reducing off-target effects and improving pharmacokinetic properties for better tolerability.
Data Source
AI summary
Disclosed are compounds of the formula:and the respective enantiomers, stereochemical isomers, hydrates, solvates, tautomers and pharmaceutically acceptable salts of such compounds; which can be useful in the treatment of various types of cancer.